Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

Tibben, J.G.; Massuger, Leon F.A.G.; Boerman, Otto C.; Borm, George F.; Claessens, R.A.M.J.; Corstens, F.H.M.

doi:10.1007/bf00182351

Cited by 11 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in humans) did not affect the magnitude of the response to endotoxin. This lack of difference in the response to the route of administration is supported by other work, including fever production after endotoxin administration (3), antibody treatment in a tumor model (33), and clondronate administration and deposition in bone (20). The physiological response (i.e., blood pressure, heart rate, and temperature) in humans in our present work is comparable to those of previous reports.…”

Section: Discussionsupporting

confidence: 90%

Acute Inflammatory Response to Endotoxin in Mice and Humans

Copeland

Warren

Lowry

et al. 2005

Clin Vaccine Immunol

356

270

View full text Add to dashboard Cite

Endotoxin injection has been widely used to study the acute inflammatory response. In this study, we directly compared the inflammatory responses to endotoxin in mice and humans. Escherichia coli type O113 endotoxin was prepared under identical conditions, verified to be of equal biological potency, and used for both mice and humans. The dose of endotoxin needed to induce an interleukin-6 (IL-6) concentration in plasma of ϳ1,000 pg/ml 2 h after injection was 2 ng/kg of body weight in humans and 500 ng/kg in mice. Healthy adult volunteers were injected intravenously with endotoxin, and male C57BL/6 mice (n ‫؍‬ 4 to 12) were injected intraperitoneally with endotoxin. Physiological, hematological, and cytokine responses were determined. Endotoxin induced a rapid physiological response in humans (fever, tachycardia, and slight hypotension) but not in mice. Both mice and humans exhibited lymphopenia with a nadir at 4 h and recovery by 24 h. The levels of tumor necrosis factor (TNF) and IL-6 in plasma peaked at 2 h and returned to baseline levels by 4 to 6 h. IL-1 receptor antagonist RA and TNF soluble receptor I were upregulated in both mice and humans but were upregulated more strongly in humans. Mice produced greater levels of CXC chemokines, and both mice and humans exhibited peak production at 2 h. These studies demonstrate that although differences exist and a higher endotoxin challenge is necessary in mice, there are several similarities in the inflammatory response to endotoxin in mice and humans.Administration of specific pathogens has proven to be a powerful tool for investigating the host's inflammatory response. Infusion of endotoxin, a cell wall component of gramnegative bacteria, is a well-established model for studying the acute inflammatory response (11,17,35). The murine endotoxin model has provided basic information resulting in dramatic improvements in understanding the inflammatory response. As a specific example, injecting endotoxin into mice led to the discovery of tumor necrosis factor (TNF) (6). Further investigation of this critical mediator of inflammation demonstrated that TNF also played a role in chronic inflammatory conditions, such as arthritis and inflammatory bowel disease. At this time, TNF inhibitors are therapies for the treatment of patients with rheumatoid arthritis (32) and Crohn's disease (23) approved by the Food and Drug Administration.Complementary studies of endotoxin administration in humans are often limited due to the risk of toxicity. On the basis of the pyrogenic response to endotoxin, humans are considered the most sensitive of all models to the effects of endotoxin (38). Despite the differences in sensitivity, the human model is useful in measuring the responses that are common to the acute inflammatory response and those responses that are specific to the endotoxin (17). Linking the murine and human models into one definitive comparison proves to be more difficult, if not impossible. A recent review article has highlighted the differences between murine and human imm...

show abstract

Section: Discussionsupporting

confidence: 90%

Acute Inflammatory Response to Endotoxin in Mice and Humans

Copeland

Warren

Lowry

et al. 2005

Clin Vaccine Immunol

356

270

View full text Add to dashboard Cite

show abstract

“…Another group demonstrated that HLA I F(ab’) 2 caused rapid neutrophil recruitment and acute rejection of human skin grafts on immunodeficient mice (18). We attempted confirm our findings in vivo with an MHC I F(ab’) 2 fragment, but were unable to achieve consistently detectable levels of circulating antibody, likely due to their short half-life in vivo (82). Nevertheless, the data reported here show that P-selectin is a critical initiator which facilitates capture of monocytes from the circulation by graft endothelium in a long-term vascularized model of AMR.…”

Section: Discussionmentioning

confidence: 92%

Blockade of P-Selectin Is Sufficient to Reduce MHC I Antibody-Elicited Monocyte Recruitment In Vitro and In Vivo

Valenzuela

Shen

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

Donor specific HLA antibodies significantly lower allograft survival, but as yet there are no satisfactory therapies for prevention of antibody-mediated rejection. Intracapillary macrophage infiltration is a hallmark of antibody-mediated rejection, and macrophages are important in both acute and chronic rejection. The purpose of this study was to investigate the Fc-independent effect of HLA I antibodies on endothelial cell activation, leading to monocyte recruitment. We used an in vitro model to assess monocyte binding to endothelial cells in response to HLA I antibodies. We confirmed our results in a mouse model of antibody-mediated rejection, in which B6.RAG1-/- recipients of BALB/c cardiac allografts were passively transferred with donor specific MHC I antibodies. Our findings demonstrate that HLA I antibodies rapidly increase intracellular calcium and endothelial presentation of P-selectin, which supports monocyte binding. In the experimental model, donor specific MHC I antibodies significantly increased macrophage accumulation in the allograft. Concurrent administration of rPSGL-1-Ig abolished antibody-induced monocyte infiltration in the allograft, but had little effect on antibody-induced endothelial injury. Our data suggest that antagonism of P-selectin may ameliorate accumulation of macrophages in the allograft during antibody-mediated rejection.

show abstract

“…only has limited effect on the targeting of i.p. growing tumors 19, 20, 21, 22, 23. Colcher et al investigated the efficacy of intracavitary radiolabeled MAb administration and demonstrated the advantage of the concomitant use of intracavitary and i.v.…”

Section: Discussionmentioning

confidence: 99%

α_vβ₃ Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide

Dijkgraaf

Kruijtzer

Frielink

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Ovarian cancer is the fourth most common cause of cancer deaths among females in the western world after cancer of the breast, colon and lung. The inability to control the disease within the peritoneal cavity is the major cause of treatment failure in patients with ovarian cancer. The majority of ovarian carcinomas express the αvβ3 integrin. Here we studied the tumor targeting potential of an 111In‐labeled cyclic RGD peptide in athymic BALB/c mice with intraperitoneally (i.p.) growing NIH:OVCAR‐3 human ovarian carcinoma tumors. The cyclic RGD peptide, c(RGDfK)E, was synthesized, conjugated with DOTA and radiolabeled with 111In. The targeting potential of 111In‐DOTA‐E‐c(RGDfK) was studied in athymic mice with i.p. growing NIH:OVCAR‐3 xenografts and the optimal dose of this compound was determined (0.01 μg up to 10 μg). The biodistribution at optimal peptide dose was determined at various time points (0.5 up to 72 hr). Furthermore, the therapeutic potential of 177Lu‐DOTA‐E‐c(RGDfK) was studied in this model. Two hours after i.p. administration, 111In‐DOTA‐E‐c(RGDfK) showed high and specific uptake in the i.p. growing tumors. Optimal uptake in the i.p. growing tumors was observed at a 0.03–0.1 μg dose range. Tumor uptake of 111In‐DOTA‐E‐c(RGDfK) peaked 4 hr p.i. [(38.8 ± 2.7)% ID/g], gradually decreasing at later time points [(24.0 ± 4.1)% ID/g at 48 hr p.i.]. Intraperitoneal growth of OVCAR‐3 could be significantly delayed by injecting 37 MBq 177Lu‐labeled peptide i.p. Radiolabeled DOTA‐E‐c(RGDfK) is suitable for targeting of i.p. growing tumors and potentially can be used for peptide receptor radionuclide therapy of these tumors. © 2006 Wiley‐Liss, Inc.

show abstract

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

Cited by 11 publications

References 14 publications

Acute Inflammatory Response to Endotoxin in Mice and Humans

Acute Inflammatory Response to Endotoxin in Mice and Humans

Blockade of P-Selectin Is Sufficient to Reduce MHC I Antibody-Elicited Monocyte Recruitment In Vitro and In Vivo

α_vβ₃ Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide

Contact Info

Product

Resources

About

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

Cited by 11 publications

References 14 publications

Acute Inflammatory Response to Endotoxin in Mice and Humans

Acute Inflammatory Response to Endotoxin in Mice and Humans

Blockade of P-Selectin Is Sufficient to Reduce MHC I Antibody-Elicited Monocyte Recruitment In Vitro and In Vivo

αvβ3 Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide

Contact Info

Product

Resources

About

α_vβ₃ Integrin‐targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide